Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06885034 · ClinicalTrials.gov registry record · Phase 1

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

A Phase 1 study of Gastrointestinal Neoplasms, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 1
Development phase
320
Enrollment target
20
Study locations

NCT06885034 is a Phase 1 study of Gastrointestinal Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 320 participants, below the 940-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06885034, a Phase 1 study of Gastrointestinal Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 1
Development phase
320 participants
Enrollment target
20
Study locations

Study Summary

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Conditions Studied

Gastrointestinal Neoplasms

Interventions

  • BIOLOGICAL GSK5764227

Study Locations (20)

Other

  • GSK Investigational Site - Bonheiden
  • GSK Investigational Site - Brussels
  • GSK Investigational Site - Leuven
  • GSK Investigational Site - Roeselare
  • GSK Investigational Site - Porto Alegre
  • GSK Investigational Site - São Paulo
  • GSK Investigational Site - Teresina
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris

California

  • GSK Investigational Site - Los Alamitos
  • GSK Investigational Site - Whittier

Texas

  • GSK Investigational Site - Houston
  • GSK Investigational Site - San Antonio

Victoria

  • GSK Investigational Site - Heidelberg
  • GSK Investigational Site - Melbourne

New York

  • GSK Investigational Site - New York

North Carolina

  • GSK Investigational Site - Durham

Washington

  • GSK Investigational Site - Wenatchee

Ontario

  • GSK Investigational Site - Toronto

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2025-06-11
Est. Completion 2028-06-23
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06885034

The ClinicalTrials.gov registry entry for NCT06885034 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 940-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (66% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which GSK5764227 is the first listed.

NCT06885034 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Texas.

Frequently Asked Questions

What is clinical trial NCT06885034 about?

NCT06885034 is a clinical study titled "A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed". This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

What is the current status of trial NCT06885034?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2025-06-11. Estimated completion is 2028-06-23.

What conditions does trial NCT06885034 study?

This clinical trial studies the following conditions: Gastrointestinal Neoplasms.

What interventions are being tested in trial NCT06885034?

The interventions under investigation include: GSK5764227 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06885034?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06885034 being conducted?

This trial has 20 study locations across California, New York, North Carolina, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.